Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3483574 | Journal of Men's Health | 2010 | 9 Pages |
Abstract
Despite combined therapeutic efforts that pursued both local control and the prevention of a systemic relapse, the prognosis of advanced primary prostatic urothelial carcinoma remains dismal. Early diagnosis appears difficult because clinical presentation differs to that of males with adenocarcinoma of the prostate or invasive transitional cell carcinoma (TCC) of the bladder. Cisplatin-based systemic chemotherapy does not allow prolonged survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Javier C. MD, PhD, Carlos MD, Javier MD, Emilio MD, Ernesto MD, José M. MD,